![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, December 24, 2012 12:34:07 PM
To expand on Jimzin's rationale,
If BIEL was to accept FDA designations of Class III on all its' products and pay Sales Reps generous commissions on sales generated by Rx's written by doctors, would they not be further ahead by this proactive approach while the FDA sorts out Class II versus Class III approvals for such safe devices?
At the moment there are no FDA approvals for anything BIEL except the Recovery Rx eye indication, so there is nothing but inertia in the US. We are the hub of pharma comedy - State of Maryland issues a financial grant so BIEL can develop sales in other countries, while FDA ponders such for 2 or 3 years? Wait....what?
Speaking of other countries, what are sales in Canada, web-based and otherwise, where the Health Canada approvals for OTC sales are in place?
I am totally convinced that Class III in the U.S. and developing Class II OTC sales in Canada and the UK for the next 12 months satisies all 3 categories - puts cash flow and value into the company through increased share price - makes every shareholder including the Whelans winners - and leads to better lives.
Season's Greetings and a prosperous and healthy 13 everyone - GO BIEL! Drug Free, Side-effect free pain relief! Go FDA!
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM